Related Experiment Video
Updated: Jan 31, 2026

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
ONS-donor ligand based Pt(II) complexes display extremely high anticancer potency through autophagic cell death
Faiz-Ur Rahman1, Amjad Ali2, Hong-Quan Duong3
1Center for Supramolecular Material and Catalysis, Department of Chemistry, Shanghai University, Shanghai, 200444, China; Department of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200438, China.
New platinum(II) complexes with ONS-donor ligands exhibit potent anticancer activity against lung, colon, and breast cancer cells, outperforming cisplatin. These compounds induce cell death through apoptosis and autophagy, offering a promising alternative cancer therapy.
Area of Science:
- Coordination Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Cisplatin is a widely used platinum-based chemotherapy drug, but its efficacy is limited by resistance and severe side effects.
- There is a continuous need for novel platinum(II) complexes with improved anticancer potency and reduced toxicity.
- ONS-donor ligands offer unique coordination properties that can influence the stability and reactivity of platinum(II) complexes.
Purpose of the Study:
- To synthesize and characterize a novel series of ONS-donor ligand-based platinum(II) complexes.
- To evaluate the in vitro anticancer activity of these complexes against various human cancer cell lines.
- To elucidate the underlying mechanisms of action, including induction of apoptosis, autophagy, and cell cycle arrest.
Main Methods:
- Synthesis of Pt(II)(R-salicylaldimine)Cl and Pt(II)(R-salicylaldimine)(4-picoline)BF4 complexes.
- Characterization using single crystal X-ray analysis, 1H NMR, LCMS, and ESI-MS.
- In vitro anticancer assays on A549, HT-29, and MDA-MB-231 cancer cell lines; assessment of apoptosis, autophagy, cell cycle, DNA interaction, and bacterial growth inhibition.
Main Results:
- The synthesized Pt(II) complexes demonstrated significant anticancer potency against non-small cell lung cancer (A549), colorectal cancer (HT-29), and triple-negative breast cancer (MDA-MB-231) cells.
- These complexes induced poly(ADP-ribose) polymerase (PARP) cleavage, inhibited colony formation, and triggered autophagic cell death via LC3-I/LC3-II expression.
- The complexes also induced p21 expression, activated Caspase3/7-dependent apoptotic signaling, modulated epithelial-mesenchymal-transition (EMT) features, and interacted with plasmid DNA.
Conclusions:
- ONS-donor ligand-based Pt(II) complexes represent a promising new class of anticancer agents with superior efficacy compared to cisplatin.
- These complexes exert their anticancer effects through multiple pathways, including apoptosis, autophagy, and cell cycle arrest.
- Further investigation into these complexes could lead to the development of novel therapeutic strategies for various cancers.
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Source And Potency Of Stem Cells
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Ligand Binding and Linkage
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

